Twist Bioscience Corp. Hits New 52-Week High at $59.90

Twist Bioscience Corp., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 59.90 on April 15, 2026. This achievement marks a notable increase from its 52-week low of USD 23.50, reflecting a substantial upward trend in the stock's performance over the past year. In the last year, Twist Bioscience Corp. has recorded a performance increase of 15.22%, although this is below the S&P 500's performance of 30.14% during the same period. The company's market capitalization stands at USD 2,760 million, indicating its position as a small-cap entity within the industry. Despite the positive movement in stock price, the company remains in a loss-making position, with a return on equity of -16.79% and a price-to-book ratio of 6.05. Additionally, the company does not offer a dividend yield, and its debt-to-equity ratio is reported at -0.41. This milestone reflects the ongoing developments within Twist Bioscience Corp. and its current standing in the competitive biotechnology landscape.